After Incyte’s commercial buy, Novartis shells out 2.7B for cancer specialist MorphoSys
Importal, MorphoSys, Acquisition (action), Incyte
UPDATE: Vertex beats own record in cystic fibrosis as next-gen treatment goes up against Trikafta
Cystic Fibrosis, Trikafta, vanza, Vertex, next-gen, Records
Sanofi guarantees employees one year of salary and support after cancer diagnosis
Workers, Malignant Neoplasms, sanofi, Affecting, Cancer Diagnosis
J&J’s Nipocalimab Demonstrates Positive Phase III and Phase II Results in Autoimmune Disorders
Nipocalimab, Sjogren’s Syndrome, Johnson and Johnson, Autoimmune Diseases, Myasthenia Gravis, Generalized, Clinical Research, Erythroblastosis, Fetal
Lilly reports mid-stage win for tirzepatide in fatty liver disease
tirzepatide, Nonalcoholic Steatohepatitis, liver scarring, Lilly reports, MASH, Clinical Trials
GSK details Blenreps PhIII combo winas it hopes to stage a turnaround in multiple myeloma
Multiple Myeloma, Blenrep, turnaround, GSK’s, Progression-Free Survival, Combined
4DMT’s Gene Therapy Reduces Eylea Injections, Advancing Plans for Phase 3 Trial in Wet AMD
Glycogen storage disease type II, 4DMT, gene therapy, Trial Phase
Updated: Novo Holdings pays $16.5B to take Catalent private and sells three manufacturing sites to Novo Nordisk
Holdings, Nordisk, deal, Acquisition (action), Investments
Takeda Appoints Former CRISPR CMO Phuong Khanh (PK) Morrow to Lead Oncology R&D Amidst Pipeline Pruning
Clustered Regularly Interspaced Short Palindromic Repeats, PK
Takeda Reports Lower Profits in Latest Quarter, Closes $300M Deal with Protagonist
Protagonist, profit, Takeda, Quarter, Report (document), earnings, Takeda’s